The CDMO is investing £6 million into a new facility at its United Kingdom site to expand its milling, micronization, and solid form capabilities.
Contract development and manufacturing organization (CDMO) Sterling Pharma Solutions is investing £6 million into a new facility at its United Kingdom site to expand its milling, micronization, and solid form capabilities. The investment in its 40-acre site in Dudley, North East England was made in response to growing demand for particle size reduction technology for pharmaceutical applications. Sterling is also expanding laboratory capabilities to provide a full solid form offering, which includes polymorph screening, salt selection, and particle engineering, and crystallization scale-up.
Four new milling areas will house a range of technologies, such as mechanical milling, spiral jet milling, and small lab-scale trial mills. To support the handling of potent and hazardous materials, the facility will also provide containment for occupational exposure band (OEB) 4 classified molecules and offer ISO 8 cleanroom environments.
Established in 1969, Sterling provides API development and manufacturing services and has a successful track record of compliance with both FDA and the UK Medicines and Healthcare products Regulatory Agency (MHRA). The investment forms part of a 15-month strategic development plan totalling almost £12 million, which will also see the expansion of the CDMO’s GMP kilo laboratories and pilot plant. The milling, micronization, and solid form facility, which is expected to be operational by mid-2018, will create more than 15 jobs over the next 18 months, bringing Sterling’s total workforce to approximately 400 employees.
Sterling will be exhibiting at CPhI Worldwide in Frankfurt, Germany, Oct. 24–26, 2017.
Source: Sterling Pharma Solutions, Stand 80M80
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Applying Appropriate Analytics to Drug Development
March 26th 2024In this episode of the Drug Solutions Podcast, Jan Bekker, Vice President of Business Development, Commercial and Technical Operations at BioCina, discusses the latest analytical tools and their applications in the drug development market.
Exosomes Field Advances with Milestones Achieved by EXO Biologics and ExoXpert
December 4th 2024EXO Biologics and ExoXpert, an EXO Biologics subsidiary, have received GMP certification of a European manufacturing facility for exosomes and have successfully loaded mRNA and DNA payloads into GMP-grade exosomes for drug delivery.